Chalouni M, Sogni P, Miailhes P, et al. - In HIV/hepatitis C virus (HCV) co-infected patients, researchers compared the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to anticipate liver-related events. The study sample consisted of 998 patients (median age was 46.8 years). By sensitivity and specificity maximization, best cutoffs to anticipate liver-related events were estimated. Investigators found that APRI had lower performance than LS and FIB-4 to anticipate HCV-related events. FIB-4 is as effective as LS in predicting HCV-related events, indicating that it can be used to treat co-infected patients with HIV/HCV and replace LS. For LS, FIB-4, and APRI, respectively, the best cutoffs to identify patients with a low or high risk of liver-related events were below 8.5, 1.00, and 0.35 and above 16.5, 4.00, and 1.75.